Prevention of diabetes by thymic hormone in alloxan-treated rats.

Yamanouchi T, Moromizato H, Kojima S, Shinohara T, Sekino N, Minoda S, Miyashita H, Akaoka I

European journal of pharmacology1 May 1994Cited by 8 (Europe PMC)

PMID8082705DOI10.1016/0014-2999(94)90691-2PepBankPUB-08082705

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, intravenous FTS pretreatment significantly suppressed alloxan-induced hyperglycemia.
In plain wordsIn rats, FTS pretreatment reduced high blood sugar caused by alloxan.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseAlloxan-induced hyperglycemia
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, intravenous FTS pretreatment significantly suppressed streptozotocin-induced hyperglycemia.
In plain wordsIn rats, FTS pretreatment reduced high blood sugar caused by streptozotocin.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseStreptozotocin-induced hyperglycemia
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270502
03AnimalAnimal study (in vivo)Other
In rats studied for toxin-induced diabetes, the effects of FTS were time dependent.
In plain wordsIn rats studied for toxin-induced diabetes, FTS effects depended on timing.
Peptide
Thymulin (serum thymic factor)
Outcome
Direction not reportedTime dependence of FTS effects
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
The effects of FTS were time dependent.
2 context sentences(design, population, supporting numbers)
Summary · context
Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia.
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, FTS suppressed hyperglycemia across a dose range of 1-6600 micrograms/kg.
In plain wordsIn rats, FTS reduced high blood sugar across the reported dose range.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseHyperglycemia suppression across dose range
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1-6600 micrograms/kg · intravenousAs given in this study (rat).
Source sentences
Summary
FTS suppressed hyperglycemia in a dose range of 1-6600 micrograms/kg.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270504
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, FTS at 40-50 micrograms/kg given 1 min before alloxan completely prevented alloxan-induced hyperglycemia.
In plain wordsIn rats, FTS given 1 min before alloxan completely prevented high blood sugar caused by alloxan.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseComplete prevention of alloxan-induced hyperglycemia
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
40-50 micrograms/kg · intravenous · 1 min before alloxan injectionAs given in this study (rat).
Source sentences
Summary
Alloxan-induced hyperglycemia was completely prevented when FTS was injected in doses of 40-50 micrograms/kg 1 min before injection of alloxan.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270505
06AnimalAnimal study (in vivo)Efficacy outcome
In alloxan-treated rats, FTS inhibited pancreatic beta-cell destruction on histological examination.
In plain wordsIn rats treated with alloxan, FTS reduced destruction of pancreatic beta-cells.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreasePancreatic beta-cell destruction
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
Histological examination of islet areas showed that alloxan-induced destruction of beta-cells was inhibited by FTS.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270506
07AnimalAnimal study (in vivo)Efficacy outcome
In rats studied for toxin-induced diabetes, FTS had no significant effect on lymphocyte subsets.
In plain wordsIn rats studied for toxin-induced diabetes, FTS did not significantly change lymphocyte subsets.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeLymphocyte subsets
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270507
08AnimalAnimal study (in vivo)Efficacy outcome
In rats studied for toxin-induced diabetes, FTS had no significant effect on immunity-related cells.
In plain wordsIn rats studied for toxin-induced diabetes, FTS did not significantly change immunity-related cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeImmunity-related cells
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270508
09AnimalAnimal study (in vivo)Mechanism
In rats studied for toxin-induced diabetes, FTS had no significant effect on plasma superoxide dismutase activity.
In plain wordsIn rats studied for toxin-induced diabetes, FTS did not significantly change plasma superoxide dismutase activity.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changePlasma superoxide dismutase activity
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Receptor activity and mechanism · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270509
10AnimalAnimal study (in vivo)Mechanism
In rats studied for toxin-induced diabetes, FTS had no significant effect on total glutathione level.
In plain wordsIn rats studied for toxin-induced diabetes, FTS did not significantly change total glutathione levels.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeTotal glutathione level
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Receptor activity and mechanism · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270510
11AnimalAnimal study (in vivo)Pharmacokinetics
In rats, exogenously injected FTS had a blood half-life of 2-3 min.
In plain wordsIn rats, injected FTS had a blood half-life of 2-3 min.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicableBlood half-life
Study
ratn: not reported in source
alloxan- or streptozotocin-treated rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
Blood half-life
2 to 3 min
exogenously injected FTS
Source sentences
Summary
The blood half-life time of exogenously injected FTS was short (2-3 min)
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats.
Report a problemFND-0808270511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.